IRX2 Antibody

What is IRX2 and what are its key characteristics?

IRX2 (Iroquois homeobox 2) is a protein encoded by the IRX2 gene in humans, also known as IRXA2, iroquois-class homeodomain protein IRX-2, or homeodomain protein IRXA2. Structurally, the protein has a molecular weight of approximately 49.1 kilodaltons. IRX2 functions as a transcription factor containing a homeodomain that binds to specific DNA sequences to regulate gene expression. The protein is primarily localized in the nucleus, consistent with its role in transcriptional regulation. IRX2 is part of the Iroquois homeobox family of transcription factors that play crucial roles in embryonic development and tissue patterning .

Which cell types and tissues express IRX2?

IRX2 expression has been documented in several cell types and tissues. Notably, IRX2 marker can be used to identify Pancreatic Endocrine Cells according to the HuBMAP Human Reference Atlas. In cardiac tissue, IRX2 is predominantly expressed in cardiac fibroblasts (CFs) rather than cardiomyocytes or endothelial cells. Research has shown that IRX2 expression is significantly upregulated in cardiac fibroblasts after angiotensin II (Ang II) treatment, and in fibrotic hearts and failing human hearts with dilated cardiomyopathy (DCM). Immunofluorescence studies have confirmed IRX2 expression in Collagen 1 (Col1)-positive fibroblasts but not in cardiac Troponin T (cTnT)-positive cardiomyocytes .

What applications are IRX2 antibodies typically used for?

IRX2 antibodies are employed in multiple research applications, depending on the specific antibody characteristics:

• Western Blot (WB): For detecting and quantifying IRX2 protein in tissue or cell lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of IRX2 in solution

• Immunofluorescence (IF): For visualizing cellular localization of IRX2

• Immunohistochemistry (IHC): For examining IRX2 expression in tissue sections

• Chromatin Immunoprecipitation (ChIP): For identifying DNA sequences bound by IRX2

Most commercial IRX2 antibodies support multiple applications, with Western blotting and immunofluorescence being the most common. When selecting an antibody, researchers should verify which applications have been validated by the manufacturer .

How should I design Western blot experiments using IRX2 antibodies?

When designing Western blot experiments with IRX2 antibodies, consider the following methodological approach:

• Sample preparation: Extract proteins from tissues or cells using appropriate lysis buffers containing protease inhibitors. For IRX2 detection in cardiac samples, RIPA buffer with complete protease inhibitor cocktail is often effective.

• Protein quantification: Determine protein concentration using Bradford or BCA assay to ensure equal loading.

• Gel electrophoresis: Load 20-50 μg of protein per lane on an 8-12% SDS-PAGE gel, as IRX2 has a molecular weight of approximately 49.1 kDa.

• Transfer and blocking: Transfer proteins to a PVDF or nitrocellulose membrane and block with 5% non-fat milk or BSA in TBST.

• Primary antibody incubation: Dilute IRX2 antibody as recommended by the manufacturer (typically 1:500 to 1:2000) and incubate overnight at 4°C.

• Controls: Include positive controls (tissue/cells known to express IRX2, such as cardiac fibroblasts) and negative controls (tissue/cells with low IRX2 expression or IRX2-knockout samples).

• Visualization: Use appropriate secondary antibodies and chemiluminescent detection systems to visualize bands at approximately 49.1 kDa.

• Normalization: Probe for housekeeping proteins (β-actin, GAPDH) to normalize IRX2 expression levels .

What considerations are important for immunofluorescence studies with IRX2 antibodies?

For successful immunofluorescence detection of IRX2:

• Sample fixation: Fix cells or tissue sections with 4% paraformaldehyde for 10-15 minutes at room temperature. For tissue sections, use fresh or frozen specimens rather than paraffin-embedded when possible, as antigen retrieval may affect antibody binding.

• Permeabilization: Since IRX2 is primarily nuclear, permeabilize samples with 0.2-0.5% Triton X-100 to ensure antibody access to nuclear antigens.

• Blocking: Block with 5-10% normal serum (matching the species of the secondary antibody) to reduce non-specific binding.

• Primary antibody: Incubate with IRX2 antibody at the manufacturer's recommended dilution (typically 1:100 to 1:500) overnight at 4°C.

• Secondary antibody: Use fluorophore-conjugated secondary antibodies matching the host species of your primary antibody.

• Co-staining: For cell type identification, co-stain with cell-specific markers. For cardiac research, consider Collagen 1 (Col1) for fibroblasts and cardiac Troponin T (cTnT) for cardiomyocytes.

• Nuclear counterstain: Since IRX2 is a nuclear protein, include DAPI or Hoechst as a nuclear counterstain to verify nuclear localization.

• Controls: Include secondary-only controls to assess background fluorescence and positive controls with known IRX2 expression patterns .

How can I use IRX2 antibodies in ChIP experiments to identify transcriptional targets?

For chromatin immunoprecipitation (ChIP) experiments with IRX2 antibodies:

• Crosslinking: Crosslink protein-DNA complexes using 1% formaldehyde for 10 minutes at room temperature.

• Chromatin fragmentation: Sonicate chromatin to generate fragments of 200-500 bp.

• Antibody selection: Choose ChIP-grade IRX2 antibodies specifically validated for this application. Different antibodies (e.g., IRX2-1B7 and IRX2-1C1) may yield slightly different binding profiles.

• Immunoprecipitation: Incubate sonicated chromatin with IRX2 antibody bound to protein A/G beads overnight at 4°C.

• Washing and elution: Perform stringent washes to remove non-specific binding, then elute and reverse crosslinks.

• DNA purification: Purify the immunoprecipitated DNA for downstream analysis.

• Target validation: Validate potential binding sites using ChIP-PCR before proceeding to genome-wide analyses like ChIP-seq.

• Bioinformatic analysis: For ChIP-seq data, analyze peak distribution with attention to promoter regions. Previous studies have shown that approximately 25-31% of IRX2 binding peaks are located in promoter transcription sites.

• Integration with transcriptomic data: Compare ChIP-seq results with RNA-seq data to identify direct transcriptional targets, as done for EGR1, which was confirmed as a direct transcriptional target of IRX2 .

How does IRX2 contribute to cardiac fibrosis mechanisms?

IRX2 plays a significant role in cardiac fibrosis through several mechanisms:

• Differential expression: IRX2 expression is significantly upregulated in cardiac fibroblasts after angiotensin II (Ang II) treatment, both in isolated cells and in Ang II infusion-induced fibrotic hearts. This upregulation is specific to cardiac fibroblasts and not observed in cardiomyocytes or endothelial cells.

• Fibroblast activation: IRX2 promotes the transformation of cardiac fibroblasts into myofibroblasts, characterized by increased expression of α-smooth muscle actin (α-SMA). This transformation is a key step in the development of cardiac fibrosis.

• Transcriptional regulation: IRX2 functions as a transcriptional activator that directly binds to the promoter region of EGR1 (Early Growth Response 1), a transcription factor known to be involved in fibrosis. ChIP-seq and luciferase assay experiments have identified specific IRX2 binding sites in the EGR1 promoter.

• In vivo significance: Cardiac fibroblast-specific knockout of IRX2 (Irx2 cfKO) or myofibroblast-specific knockout (Irx2 mfKO) in mice significantly attenuates Ang II-induced cardiac fibrosis, reduces fibrotic area, and decreases the expression of fibrotic markers such as Col1 and Col3. Conversely, myofibroblast-specific overexpression of IRX2 (Irx2 mfTg) exacerbates these fibrotic responses.

• Cardiac function impact: Deletion of IRX2 in cardiac fibroblasts or myofibroblasts improves cardiac function in Ang II-infused mice, as evidenced by elevated ejection fraction (EF) and reduced left ventricular internal diameter in diastole (LVIDd).

These findings suggest that IRX2 antibodies can be valuable tools for studying cardiac fibrosis mechanisms, particularly in tracking IRX2 expression in cardiac fibroblasts and examining its interaction with downstream targets like EGR1 .

What are the key considerations for validating IRX2 antibody specificity?

Validating IRX2 antibody specificity is crucial for ensuring reliable experimental results:

• Genetic validation: Test the antibody in IRX2 knockout or knockdown models. For example, validate using tissues or cells from IRX2 conditional knockout mice (Irx2 fl/fl) treated with Cre recombinase, which should show significantly reduced or absent signal compared to controls.

• siRNA/shRNA validation: Use IRX2-specific siRNA or shRNA to knock down IRX2 expression and confirm reduced antibody signal. Research has utilized shRNA-mediated interference approaches with multiple constructs (e.g., shIrx2 #1 and #2) to validate specificity.

• Overexpression systems: Complementary to knockdown approaches, test the antibody in IRX2 overexpression systems, such as adenovirus-mediated IRX2 overexpression in cardiac fibroblasts, which should show increased signal intensity.

• Western blot analysis: Confirm the antibody detects a single band of the expected molecular weight (approximately 49.1 kDa) in Western blot applications.

• Immunoprecipitation: Perform immunoprecipitation followed by mass spectrometry to confirm the antibody is pulling down IRX2 protein.

• Cross-reactivity assessment: Test the antibody on tissues from different species to confirm the expected cross-reactivity pattern. Many IRX2 antibodies show reactivity to human, mouse, and rat IRX2, but this should be empirically verified.

• Peptide competition: Conduct peptide competition assays using the immunizing peptide to confirm signal specificity.

• Application-specific validation: Validate the antibody for each specific application (WB, IF, IHC, ChIP) as performance can vary significantly between applications .

How can IRX2 antibodies be used to study transcriptional networks?

IRX2 antibodies can be powerful tools for studying transcriptional networks through several approaches:

• ChIP-seq analysis: Use IRX2 antibodies in ChIP-seq experiments to identify genome-wide binding sites. Studies have shown that approximately 25-31% of IRX2 binding peaks are located in promoter transcription sites, indicating direct transcriptional regulation of target genes.

• Integrated genomic approaches: Combine ChIP-seq with RNA-seq to identify genes that are both bound by IRX2 and differentially expressed upon IRX2 modulation. This approach identified EGR1 as a direct transcriptional target of IRX2 in cardiac fibroblasts.

• Transcription factor complex identification: Use IRX2 antibodies for co-immunoprecipitation experiments to identify protein partners that form transcriptional complexes with IRX2.

• Luciferase reporter assays: Confirm direct transcriptional regulation by IRX2 using luciferase reporter constructs containing potential IRX2 binding sites. Mutating these binding sites should abolish IRX2-mediated transcriptional activation, as demonstrated for EGR1 regulation.

• Dynamic transcriptional responses: Track IRX2 binding to promoters under different stimulation conditions (e.g., Ang II treatment) to understand context-dependent transcriptional regulation.

• Single-cell approaches: Use IRX2 antibodies in combination with single-cell technologies to understand cell-type-specific transcriptional networks.

• Spatial transcriptomics: Combine IRX2 immunostaining with spatial transcriptomics to correlate IRX2 protein expression with transcriptional profiles in tissue context.

This multi-faceted approach can reveal the complex transcriptional networks regulated by IRX2 in different biological contexts .

What are common issues with IRX2 antibodies and how can they be resolved?

Researchers may encounter several challenges when working with IRX2 antibodies:

• High background signal:

  • Solution: Optimize blocking conditions by testing different blocking agents (BSA, normal serum, commercial blockers)

  • Increase washing steps duration and frequency

  • Try more dilute antibody concentrations

  • Use more specific secondary antibodies

• Weak or no signal:

  • Solution: Test different fixation protocols as overfixation can mask epitopes

  • Try heat-mediated or enzymatic antigen retrieval methods

  • Increase antibody concentration or incubation time

  • Ensure protein expression in your sample (use positive controls)

  • Check sample preparation to ensure protein integrity

• Multiple bands in Western blot:

  • Solution: Optimize lysis conditions to prevent protein degradation

  • Include protease inhibitors in all buffers

  • Test different antibody dilutions

  • Use more stringent washing conditions

  • Consider testing alternative IRX2 antibodies raised against different epitopes

• Inconsistent ChIP results:

  • Solution: Optimize crosslinking conditions

  • Adjust sonication parameters to ensure proper chromatin fragmentation

  • Increase antibody amount for immunoprecipitation

  • Use ChIP-grade antibodies specifically validated for this application

  • Optimize PCR conditions for ChIP-PCR validation

• Species cross-reactivity issues:

  • Solution: Verify the antibody's species reactivity before purchase

  • Consider species-specific antibodies if working with non-human models

  • Test the antibody on known positive controls from your species of interest

How can I analyze contradictory results from IRX2 antibody experiments?

When faced with contradictory results using IRX2 antibodies:

• Antibody variation: Different antibodies targeting different epitopes of IRX2 may yield different results. Compare antibodies targeting N-terminal, C-terminal, or internal regions of IRX2. For example, some suppliers offer antibodies specifically targeting the C-terminal region (e.g., Aviva Systems Biology's Irx2 antibody - C-terminal region).

• Technical considerations:

  • Evaluate cell/tissue preparation methods, as different extraction protocols may expose different epitopes

  • Consider fixation differences between methods (e.g., paraformaldehyde for IF vs. methanol for IHC)

  • Assess antibody concentrations and incubation conditions across experiments

• Biological context:

  • IRX2 expression and function may be context-dependent

  • Consider cell type differences (e.g., IRX2 is expressed more highly in cardiac fibroblasts than cardiomyocytes)

  • Evaluate experimental stimulation conditions (e.g., Ang II treatment upregulates IRX2)

  • Assess developmental timing or disease state of samples

• Control experiments:

  • Perform side-by-side comparisons with multiple antibodies

  • Include genetic approaches (siRNA, CRISPR knockout) to validate antibody specificity

  • Use recombinant IRX2 protein as a positive control

• Orthogonal approaches:

  • Supplement antibody-based detection with mRNA analysis

  • Consider mass spectrometry-based protein detection

  • Use fluorescent protein tagging (GFP-IRX2) for localization studies

What controls should be included in IRX2 antibody experiments?

Proper controls are essential for reliable interpretation of IRX2 antibody experiments:

• Positive controls:

  • Tissues or cells known to express IRX2 (e.g., cardiac fibroblasts)

  • Samples treated with stimuli known to upregulate IRX2 (e.g., Ang II-treated cardiac fibroblasts)

  • Recombinant IRX2 protein or IRX2-overexpressing cells

• Negative controls:

  • IRX2 knockout or knockdown samples

  • Cells/tissues with naturally low IRX2 expression

  • For immunostaining, secondary antibody-only controls to assess background

• Specificity controls:

  • Peptide competition assays to confirm epitope specificity

  • Multiple antibodies targeting different regions of IRX2

  • Isotype control antibodies matching the primary antibody's isotype

• Technical controls:

  • Loading controls for Western blot (β-actin, GAPDH, etc.)

  • Internal staining controls for IHC/IF (cell type markers)

  • Input chromatin for ChIP experiments

  • IgG control for immunoprecipitation experiments

• Biological controls:

  • Multiple biological replicates

  • Different cell types or tissues with varying IRX2 expression

  • Time course experiments to track dynamic changes

  • Dose-response studies for treatments affecting IRX2 expression

What are emerging research areas involving IRX2 antibodies?

Several emerging research areas involve IRX2 antibodies:

• Fibrosis mechanisms: IRX2 is implicated in cardiac fibrosis through regulation of the EGR1 pathway. Research is expanding to investigate IRX2's role in fibrosis in other organs and tissues.

• Cardiac disease: Studies have shown IRX2 upregulation in failing human hearts with dilated cardiomyopathy (DCM), suggesting broader implications in cardiac pathophysiology.

• Developmental biology: As a member of the Iroquois homeobox family, IRX2 likely plays important roles in embryonic development and tissue patterning that remain to be fully elucidated.

• Cancer research: Homeobox genes often have altered expression in cancer, suggesting potential investigations of IRX2 in oncogenesis and tumor progression.

• Therapeutic targeting: Understanding IRX2's role in disease processes may lead to therapeutic approaches targeting this transcription factor or its downstream effectors.

• Single-cell analysis: Integration of IRX2 antibodies with single-cell technologies could reveal cell-type-specific functions and heterogeneity in IRX2 expression and activity.

• 3D tissue models: Using IRX2 antibodies in organoids and other 3D tissue models may provide insights into its function in more physiologically relevant contexts .

How do experimental models affect IRX2 antibody selection and validation?

Different experimental models require specific considerations for IRX2 antibody selection and validation:

• Species-specific considerations:

  • Mouse models: Many IRX2 antibodies are validated for mouse samples, but verify specific reactivity

  • Human samples: Clinical samples require antibodies validated for human IRX2

  • Cross-species studies: Select antibodies with confirmed cross-reactivity to relevant species

• Model-specific validation:

  • Primary cells vs. cell lines: Antibody performance may differ between primary cells (e.g., primary cardiac fibroblasts) and immortalized cell lines

  • Tissue sections: Consider tissue-specific fixation and antigen retrieval requirements

  • 3D cultures/organoids: May require optimized penetration and detection protocols

• Genetic models:

  • Knockout validation: Use conditional knockout models (e.g., Irx2 fl/fl with tissue-specific Cre expression) to confirm antibody specificity

  • Transgenic overexpression: Models like Irx2 mfTg (myofibroblast-specific IRX2 transgenic mice) can serve as positive controls

  • Reporter systems: Consider models with tagged IRX2 for validation purposes

• Disease models:

  • Fibrosis models: Ang II infusion models show increased IRX2 expression in cardiac fibroblasts

  • Heart failure models: DCM models exhibit elevated IRX2 levels

  • Model-specific timing: Consider temporal dynamics of IRX2 expression in disease progression

• Technical adaptations:

  • Fresh vs. fixed samples: Some antibodies perform better in fresh-frozen vs. fixed tissues

  • Antigen retrieval methods: Different models may require specific retrieval protocols

  • Detection systems: Consider signal amplification for models with low IRX2 expression